Fulcrum Therapeutics FULC 深 沪
交易中 02-03 11:06:20 美东时间
10.615
-0.105
-0.98%
华盛通- 最 高10.905
- 今 开10.73
- 成交量 4.10万股
- 最 低 10.53
- 昨 收 10.72
- 总市值 7.00亿
- 52周最高 15.7399
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.315
- 委 比 75.27%
- 总股本 6597.03万
- 历史最高 33.098
- 量 比 0.39
- 振 幅 3.50%
- 历史最低 2.25
- 每 手 1
- 风险率 2.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-12 21:54
JP Morgan Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $20
JP Morgan initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $20.
01-12 20:33
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics granted 30,400 stock options to three new employees under its 2022 Inducement Stock Incentive Plan, with an exercise price of $10.84 per share. The options vest over four years and have a ten-year term. The company focuses on developing small-molecule therapies for genetically defined rare diseases, including its lead program, pociredir, for sickle cell disease.
01-09 21:30
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Toll Brothers Posts Mixed Q4 Results, Joins Almonty Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around...
2025-12-09 21:08
美股牛股 | “减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%
“减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%，IBM拟110亿美元收购该公司>>
2025-12-09 17:40
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
